Investor Presentaiton

On track to complete Shield-Lung enrollment in 2025 >7K Currently enrolled Enrolling individuals who meet USPSTF Criteria for High-Risk Lung Cancer Screening1 Negative for lung cancer + One-year follow-up Low- dose CT + Lung cancer First endpoint readout in 2026 GUARDANT™ 1. Nguyen, et al. 2023. Screening for high frequency malignant disease (SHIELD)J Clin Oncol 41, 2023 (suppl 16; abstr TPS1610). 2.https://clinicaltrials.gov/study/NCT05117840 INVESTOR 20 DAY 23 131

View entire presentation